S'abonner

A blood-based host gene expression assay for early detection of respiratory viral infection: an index-cluster prospective cohort study - 25/02/21

Doi : 10.1016/S1473-3099(20)30486-2 
Micah T McClain, MD a, b, c, , Florica J Constantine, MS a, Bradly P Nicholson, PhD d, Marshall Nichols, MS a, Thomas W Burke, PhD a, Ricardo Henao, PhD a, Daphne C Jones, MD c, Lori L Hudson, PhD a, L Brett Jaggers, MD b, Timothy Veldman, PhD a, Anna Mazur, MS a, Lawrence P Park, PhD b, c, Sunil Suchindran, PhD a, Ephraim L Tsalik, MD a, b, c, Geoffrey S Ginsburg, MD a, Christopher W Woods, MD a, b, c
a Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, NC, USA 
b Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA 
c Durham VA Medical Center, Durham, NC, USA 
d Institute for Medical Research, Durham, NC, USA 

* Correspondence to: Dr Micah T McClain, Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA Division of Infectious Diseases Duke University Medical Center Durham NC 27710 USA

Summary

Background

Early and accurate identification of individuals with viral infections is crucial for clinical management and public health interventions. We aimed to assess the ability of transcriptomic biomarkers to identify naturally acquired respiratory viral infection before typical symptoms are present.

Methods

In this index-cluster study, we prospectively recruited a cohort of undergraduate students (aged 18–25 years) at Duke University (Durham, NC, USA) over a period of 5 academic years. To identify index cases, we monitored students for the entire academic year, for the presence and severity of eight symptoms of respiratory tract infection using a daily web-based survey, with symptoms rated on a scale of 0–4. Index cases were defined as individuals who reported a 6-point increase in cumulative daily symptom score. Suspected index cases were visited by study staff to confirm the presence of reported symptoms of illness and to collect biospecimen samples. We then identified clusters of close contacts of index cases (ie, individuals who lived in close proximity to index cases, close friends, and partners) who were presumed to be at increased risk of developing symptomatic respiratory tract infection while under observation. We monitored each close contact for 5 days for symptoms and viral shedding and measured transcriptomic responses at each timepoint each day using a blood-based 36-gene RT-PCR assay.

Findings

Between Sept 1, 2009, and April 10, 2015, we enrolled 1465 participants. Of 264 index cases with respiratory tract infection symptoms, 150 (57%) had a viral cause confirmed by RT-PCR. Of their 555 close contacts, 106 (19%) developed symptomatic respiratory tract infection with a proven viral cause during the observation window, of whom 60 (57%) had the same virus as their associated index case. Nine viruses were detected in total. The transcriptomic assay accurately predicted viral infection at the time of maximum symptom severity (mean area under the receiver operating characteristic curve [AUROC] 0·94 [95% CI 0·92–0·96]), as well as at 1 day (0·87 [95% CI 0·84–0·90]), 2 days (0·85 [0·82–0·88]), and 3 days (0·74 [0·71–0·77]) before peak illness, when symptoms were minimal or absent and 22 (62%) of 35 individuals, 25 (69%) of 36 individuals, and 24 (82%) of 29 individuals, respectively, had no detectable viral shedding.

Interpretation

Transcriptional biomarkers accurately predict and diagnose infection across diverse viral causes and stages of disease and thus might prove useful for guiding the administration of early effective therapy, quarantine decisions, and other clinical and public health interventions in the setting of endemic and pandemic infectious diseases.

Funding

US Defense Advanced Research Projects Agency.

Le texte complet de cet article est disponible en PDF.

Plan


© 2021  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 21 - N° 3

P. 396-404 - mars 2021 Retour au numéro
Article précédent Article précédent
  • T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study
  • Chris Ka Pun Mok, Airu Zhu, Jingxian Zhao, Eric H Y Lau, Junxiang Wang, Zhao Chen, Zhen Zhuang, Yanqun Wang, Abeer N Alshukairi, Salim A Baharoon, Wenling Wang, Wenjie Tan, Weiwen Liang, Jamiu O Oladipo, Ranawaka A P M Perera, Sulyman A Kuranga, Malik Peiris, Jincun Zhao
| Article suivant Article suivant
  • The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006–17): a multicentre, retrospective observational study
  • Clara Inés Agudelo, Carlos Castañeda-Orjuela, Maria Cristina de Cunto Brandileone, Gabriela Echániz-Aviles, Samanta Cristine Grassi Almeida, María Noemí Carnalla-Barajas, Mabel Regueira, Sofia Fossati, Pedro Alarcón, Pamela Araya, Carolina Duarte, Jacqueline Sánchez, Mirna Novas, Gilda Toraño-Peraza, Misladys Rodríguez-Ortega, Gustavo Chamorro-Cortesi, Anibal Kawabata, Gabriela García-Gabarrot, Teresa Camou, Enza Spadola, Daisy Payares, Ana Lucía Andrade, José Luis Di Fabio, Elizabeth Castañeda, SIREVA Working Group, A Corso, Paula Gaguetti, Omar Veliz, C S Pereira, D Napoli, M A Moscoloni, M L L Silva e Guerra, S Bokermann, Lincoln S do Prado, U J Días, J C Hormazabal, B Rojas, S Castro, D Ibáñez, J Fernandez, O Sanabria, J Moreno, Z Alarcón, M K Rodriguez, A Bautista, L P Solis, D S Apaza, M A Capote, J M Feris, D Cedano, Araceli Soto-Noguerón, Maria E Velázquez-Meza, Margarita Hernández-Salgado, M E León, Minako Nagai, Liliana Rojas, M L Vega, G P Giffoni, V Félix

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.